



SLEEP DISORDERS

Daniel F. Kripke, MD
UC, San Diego
and The Scripps Clinic Sleep Center

revised from a collaboration with

Andrea Fagiolini, MD
University of Pittsburgh

Pre-Lecture Exam

Question 1

- 1. The most common cause of insomnia is**
 - A. Use of sleeping pills
 - B. Poor sleeping habits
 - C. Psychiatric disturbance
 - D. Alcoholism
 - E. Sleep apnea

Question 2

- 2. Effective treatment for chronic insomnia may include:**
- A. Zaleplon
 - B. Sleep restriction therapy
 - C. Zolpidem
 - D. Quazepam
 - E. Triazolam

Question 3

- 3. Benefits of hypnotics outweigh risks:**
- A. For insomnia due to medical conditions
 - B. For hospice care
 - C. To prevent depression
 - D. To improve daytime alertness
 - E. All of the above

Question 4

4. A hypnotic which causes little daytime sedation is:
- A. Lorazepam
 - B. Zolpidem
 - C. Temazepam
 - D. Flurazepam
 - E. Diphenhydramine

Question 5

- 5.** The usual maximum dose of zolpidem for an elderly woman is
- A. 6.25 mg
 - B. 10 mg
 - C. 15 mg
 - D. 20 mg
 - E. 25 mg

Question 6

- 6. The most popular drug for sleep complaints accompanying depression is:**
- A. Zolpidem
 - B. Zaleplon
 - C. Trazodone
 - D. Melatonin
 - E. Temazepam

Question 7

- 7. A hypnotic which helps people fall asleep when taken at bedtime is:**
- A. Zaleplon
 - B. Temazepam
 - C. Lorazepam
 - D. Oxazepam
 - E. Ethchlorvynol

Question 8

- 8. The most common cause of excessive sleep is:**
- A. Primary hypersomnia
 - B. Depression
 - C. Tricyclic antidepressants
 - D. Sleep apnea
 - E. Irregular habits

Question 9

- 9. Useful treatments for sleep apnea include:**
- A.** Mandible and tongue appliances
 - B.** Dieting
 - C.** Sleep position training
 - D.** Continuous positive airway pressure
 - E.** All of the above

Question 10

10. To treat delayed sleep phase, use:

- A. Vitamin B6
- B. Relaxation and sleep hygiene
- C. Methylphenidate
- D. Bright light in the morning
- E. Bright light just before bedtime



OUTLINE

- **Sleep disorders: definitions**
- **Insomnia**
- **Hypnotics: risks and choices**
- **Cognitive behavioral therapy (CBT)**
- **Sleep apnea**
- **Narcolepsy**
- **PLMD (periodic limb movements)**
- **Circadian rhythm sleep disorders**



KEY POINTS

- **Cognitive-behavioral therapy is best for chronic insomnia**
- **Hypnotics risks usually outweigh benefits**
- **Sleep apnea is the most common cause of excess sleepiness**
- **Circadian rhythm disorders can be treated using the light phase response curve**

SLEEP DISORDERS

- **Primary**
- **Comorbid:**
 - **Related to Another Mental Disorder**
 - **Due to a General Medical Condition**
 - **Substance-Related**

SLEEP DISORDERS

- **Insomnia**
- **Breathing disorders**
- **Hypersomnia & narcolepsy**
- **Circadian disorders**
- **Parasomnias**
- **Movement disorders**



INSOMNIA: 1) Sleep Difficulty

- Complaints of disturbed sleep in the presence of adequate opportunity and circumstance for sleep
 - (1) difficulty in initiating sleep
 - (2) difficulty in maintaining sleep or
 - (3) waking up too early
 - ? nonrestorative or poor-quality sleep
- **NIH conference on chronic insomnia**
<http://consensus.nih.gov/2005/2005InsomniaSOS026html.htm>



INSOMNIA: 2) Daytime Hyperarousal

Some patients with chronic insomnia have daytime hyperarousal and are not able to fall asleep in the day. They might be fatigued, but they are not sleepy.



INSOMNIA:


3) Functional Impairment Associated

- Several studies show decreased quality of life and impaired daytime function associated with insomnia.
- However, it is difficult to distinguish any causal effects of insomnia from effects of comorbidities such as depression and anxiety.



- **Most insomnia is comorbid with other disorders, especially depression, substance abuse and anxiety.**
- **In comorbid insomnia, it is unclear when treatment focus should be on comorbidities.**
- **Primary insomnia is insomnia without comorbidities.**

Prevalence of Insomnia in U.S.






INSOMNIA TREATMENTS

- **Cognitive-behavioral therapy: best demonstrated long-term efficacy and least side effects**
- **Hypnotics: most hypnotics not recommended for more than 1 month's use**
- **Sedative antidepressants: little data**

CHRONIC INSOMNIA

- Most insomnia is chronic
- Lasts for years
- Natural history not well studied
- Primary and comorbid insomnia hard to distinguish



NIH conference on chronic insomnia found better evidence for cognitive-behavioral treatments than for long-term pharmacologic agents.

● <http://consensus.nih.gov/2005/2005InsomniaSOS026html.htm>



COGNITIVE-BEHAVIORAL TREATMENT of INSOMNIA

- **Cognitive treatment (why “Not to worry!”)**
- **Sleep hygiene (education and counseling)**
- **Relaxation therapies (e.g., deep breathing, meditation, muscle relaxation)**
- **Sleep restriction therapy (limitation of time spent in bed)**





COGNITIVE ELEMENT:

- **The healthiest people sleep 6.5 – 7.5 hours. It is safer to sleep 5-6 hours than 8-10 hours.**
- **The average adult in the U.S. sleeps 6.5 hours: most do not need 8 hours.**
- **It is normal for older people to awaken often at night.**
- **People with insomnia live longer than people without insomnia: Not to worry!**
- **Harmful to spend longer in bed than you can sleep**

NOT MUCH RISK TO
SLEEPING 5-6 HOURS

8 HOURS SLEEP
HIGHER MORTALITY



It is safe not to
sleep 8 hours,
as long as patient
is not too sleepy:

Kripke et al., *Arch.
Gen. Psychiatry*
2002;59:131-136

HOURS of SLEEP



GOOD SLEEP HYGIENE

- **Sleep hygiene**
 - consistent bedtime and wake time
 - Do not spend extra hours in bed to make up for poor sleep
 - No long daytime naps (e.g. 90 min)
 - Can try 15 - 40 min naps and closely follow sleep logs to decide if naps are OK
 - Don't go to bed unless sleepy
- **Avoid caffeine from mid afternoon on**
- **Limit alcohol in the evening**
- **Use bedroom only for sleeping and sex**

AVOID ALERTING IN BED

- **If patient needs to spend time worrying, do it in a worry chair**
- **Mystery books and watching TV should be avoided in bed.**
- **Where possible, do alerting activities outside the bedroom**



SLEEP RESTRICTION

- Reducing time-in-bed has powerful and lasting benefits for insomnia
- E.g., patient who says she only sleeps 6 hours should reduce time-in-bed to 6 hours
- Correct negative conditioning to the bedtime experience: **RELEARN that when you go to bed you habitually go to sleep.**

SLEEP RESTRICTION

- If patient is sleeping >85% of time in bed, may increase time in bed by 15 min. per week
- If patient reports sleeping <85% of time in bed, then time in bed should be reduced
- Maintain regular get-up time

Measures That Can Decrease Sleep Latency

- **Tension-release relaxation exercises: meditative, autogenic, Jacobsonian, etc.**
- **Decreased stimulation prior to bedtime (avoid “action” movies, arguments, etc.)**
- **Light bedtime snack (perhaps milk or other tryptophan-increasing foods, e.g., carbohydrates, dairy products)**



Hypnotics:

Only 3 approved for Long-Term Use

**FDA-approved based on 6-month studies
with subjective data for efficacy:**

- **Eszopiclone**
- **Zolpidem tartrate extended release**
- **Ramelteon**

Hypnotics for Short-Term Use

SHORT Half - Life

Zolpidem: receptor specificity, low rebound, favorable kinetics

Triazolam: favorable kinetics, high rebound, strange behavioral and memory problems

Zaleplon: receptor specificity, half life too short

Receptor specificity may limit muscle-relaxing and anti-anxiety effects.

Hypnotics for Short-Term Use

MEDIUM Half – Life, Some Hangover:

Temazepam: onset ~1 hour, daytime sedation

Lorazepam: onset ~1 hour, daytime sedation

Estazolam: daytime sedation

Alprazolam?




Long Half-Life Hypnotics for Short-Term Use:

- Flurazepam and quazepam
- Diazepam: rapid absorption, first-pass short half life, but active metabolites accumulate
- Because of delayed accumulation and delayed elimination risk, **daytime sedation, increased falls, and confusion**, long half-life hypnotics are not generally indicated, especially for elders

● HALF-LIFE EFFECTS ON PLASMA LEVELS

● DAY vs. NIGHT EFFECTS




HALF LIVES OF HYPNOTICS

----- ~ 8 HOURS ——— ~ 2 HOURS - · - · - ~ 48 HOURS +

■ SLEEP TIME

| | | | |
|-----------|-----------|-----------|------------|
| EXAMPLES: | TEMAZEPAM | TRIAZOLAM | DIAZEPAM |
| | LORAZEPAM | ZOLPIDEM | FLURAZEPAM |
| | OXAZEPAM | | QUAZEPAM |



**Predicted
HANGOVER.
Zolpidem
sustained
release ?
similar to
eszopiclone**

Adapted from:
Drover, D.R.
Clin. Pharmacokinetics.
2004;43:227-238.

META - ANALYSIS

A new NIH-sponsored meta-analysis has raised a question whether the new benzodiazepine agonists (“Z” drugs) produce any significant increase in objective (EEG) total sleep time for chronic insomnia.*

*Buscemi N, Vandermeer B, Friesen C et al. The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-analysis of RCTs. *J Gen Intern Med* 2007;22:1335-50.



META - ANALYSIS

Advantage of Benzodiazepine Agonists (Z drugs) vs. Placebo

| | OBJECTIVE | SUBJECTIVE |
|------------------------|-------------------------------------|--------------------------------------|
| Total Sleep Time | 11.4 min (-0.5, 23.2) ^{NS} | 31.5 min (25.6, 37.5) |
| Sleep Onset Latency | -12.8 min (-17, -9) | -17.0 min (-20, -14) |
| Wake After Sleep Onset | -7.0 min (-14.6, 0.7) ^{NS} | -15.0 min (-19.1, 4.9) ^{NS} |
| Sleep Efficiency | 4.7% (3.1, 6.2) | 5.0% (1.5, 8.6) |

The numbers represent benefits of drug versus placebo (mean and 95% confidence limits). For Total Sleep Time and Sleep Efficiency, a positive increase was desirable, but for Sleep Onset Latency and Wake After Sleep Onset, a negative decrease indicated benefit.

Objective benefits for Total Sleep Time and Wake After Sleep Onset were **NOT significant = NS**. Subjective benefits were greater but not impressive.

META - ANALYSIS

- This new meta-analysis found that the drug groups had a “significantly higher **risk of harm**” than placebo, that is, participants taking “Z” drugs experienced more adverse symptoms.
- There was strong evidence for **publication bias**, that is, unpublished results were quite likely worse than the results published and analyzed.



ANOTHER META - ANALYSIS: OVER AGE 60, RISKS > BENEFITS: Hypnotics Not Recommended

- Number needed to treat for improved sleep quality was **13**.
- Number needed to harm for any adverse event was **6!**

Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. *BMJ* 2005 November 11.



DAYTIME IMPAIRMENT

- Preponderance of objective evidence that all hypnotics result in daytime **impairment**, NOT improved function.
- However, recent trials have demonstrated **subjectively reported improvements** in function.
- Note the disjunction between objective and subjective measures of benefit.




DAYTIME IMPAIRMENT

- Daytime impairment is much worse from hypnotics with half-life $\gg 4$ hours.
- Risks include increased automobile accidents, falls, memory loss, and confusion.

DAYTIME IMPAIRMENT

- Because of its very short half-life, zaleplon probably does not cause daytime impairment, even when taken in the middle of the night.
- However, the clinical value of middle-of-the-night use has not been well demonstrated.

REBOUND INSOMNIA



After 6 months eszopiclone 3 mg., on the first withdrawal night, the hypnotic group slept WORSE than the placebo group. Adapted from Walsh JK, Krystal AD,

Amato DA et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. *Sleep* 2007;30(8):959-68.

REBOUND INSOMNIA

Likewise, a patient taking zolpidem a few times a week sleeps worse on nights skipping medication than after skipping placebo.

Walsh JK. Zolpidem "as needed" for the treatment of primary insomnia: A double-blind placebo-controlled study. Sleep Medicine Reviews 2002;6(Suppl. 1):S7-S11. See correction pp. 195-196.

OVERDOSE

- Acute ingestion of benzodiazepine agonists alone rarely causes death.
- Benzodiazepines combined with alcohol or other sedating drugs may be lethal.
- Barbiturates, ethchlorvynol, glutethimide, etc. may be much **more lethal**.



**Twelve STUDIES FOUND
INCREASED MORTALITY
ASSOCIATED WITH HYPNOTICS USE***

Kripke et al 1979
Allgulander et al 1987
Allgulander et al 1990
Rumble and Morgan 1992
Thorogood et al 1992
Merlo et al 1996
Sundquist et al 1996
Kojima et al 2000
Kripke et al 2002
Mallon et al 2002
Ahman & Bath 2005
Hausken et al 2007

* Causality unproven. Unknown if applies to the most modern hypnotics.

QUESTION of DEPRESSION RISK

| | SUBJECTS | DEPRESSED |
|----------------------------------|-----------------|------------------|
| TOTAL OF 4 HYPNOTICS | 5535 | 109 (2.0%) |
| TOTAL OF 4 PLACEBO GROUPS | 2318 | 21 (0.9%) |

In randomized trials of zolpidem, zaleplon, eszopiclone, and ramelteon, depression was reported more often in drug than placebo groups:

Chi Square = 10.39, $p < 0.002$, risk ratio = 2.2

Kripke DF. *BMC Psychiatry* 2007;7:42.

Question of Infection and Cancer

- **In controlled trials of zolpidem, zaleplon, eszopiclone, and perhaps ramelteon, more frequent infections and cancers were reported in drug than placebo groups. The significance is not yet understood.**

Zolpidem the market leader


Comfortable Position

Prescriptions for sleeping pills are increasing, with Ambien continuing to lead those in its class.

NYTimes.com 3/8/06

Source: IMS Health

NUMBER OF PRESCRIPTIONS WRITTEN FOR NONBARBITURATE SLEEPING PILLS



* Includes Temazepam, Triazolam and other benzodiazepines

Trazodone and antihistamines are also frequently used as hypnotics.

Zolpidem Clinical Effects

- **Rapid onset of action**
 - Often under 30 minutes
 - Take just prior to going to bed
- **Hypnotic effect precedes myorelaxant effect**
 - Most patients don't feel sleepy first, so they can fall asleep anywhere without warning

Zolpidem Clinical Effects

- **Prolongs total sleep 20 - 45 min. or less**
 - **May make early AM insomnia worse**
- **Maximum dosage:**
 - **Adults: 10 mg or 12.5 mg (extended release)**
 - **Elderly: 5 or 6.25 mg (extended release)**



| | Eszopiclone | Zolpidem |
|----------------------|--|--|
| HALF LIFE | 6 hours (9 hours in elderly) | 2.6 hours (? 3 hours in elderly) |
| RECEPTOR SPECIFICITY | Medium | High |



ESZOPICLONE

- FDA permitted an indication for long-term use, 2005
- Several studies have claimed improved functioning with long-term use, based on subjective data.*
- However, severe adverse effects were 3 times as common with eszopiclone as with placebo.*
- Dropouts for depression were 12 in the eszopiclone group and 0 in the placebo group.*

* Krystal AD, Walsh JK, Laska E et al. *Sleep* 2003;26(7):793-9.



ESZOPICLONE

- **Likely to produce more hangover than zolpidem or zaleplon**
- **Impairs morning digit symbol substitution as compared to placebo**
- **Same active ingredient as zopiclone, which was associated with excess auto accidents in Europe**
- **Maximum dosage 3 mg. (2 mg. elderly)**



UNCOMMON ADVERSE EFFECTS OF “Z” DRUGS

- **Hallucinations**
- **Somnambulistic night eating
or “Zombie driving”**
- **Confusion**



RAMELTEON

- **FDA approved long-term use indication, 2005**
- **Melatonin agonist**
- **Does not bind to benzodiazepine-GABA receptor: no cross-tolerance**
- **Complex metabolism, active metabolites**



RAMELTEON

- **Little benefit:** Appears to reduce sleep latency 7 – 16 min, but has little value for maintaining sleep—similar to melatonin
- **Little dose-response:** 8 mg. for everyone



RAMELTEON

- **Likely to have no risk of dependency and less other risks than benzodiazepine agonists**
- **Possible affects on reproductive endocrinology, e.g., prolactin, testosterone**

META – ANALYSIS of ANTIDEPRESSANTS*

- **According to meta-analysis of a very small number of studies, antidepressants may produce more benefit for sleep than benzodiazepine agonists.**

***Buscemi N, Vandermeer B, Friesen C et al. The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-analysis of RCTs. *J Gen Intern Med* 2007;22:1335-50.**

TRAZODONE for INSOMNIA

- **Dose: 25 - 50mg; low-adipose patients usually require less**
- **Onset of action: 20-60 minutes**
 - **Average peak level in 23 minutes**
- **Effect on sleep stages:**
 - **Increases stage 4**
 - **Slight decrease in REM**



TRAZODONE for INSOMNIA

- **Advantages**
 - Rapid onset of action
 - Usually minimal or no tolerance develops
 - May be antidepressant or augment other antidepressants
- **Disadvantages**
 - Hypotension, dizziness
 - Daytime sedation ~20% of patients
 - GI disturbance
 - Priapism in men (1:800 to 1:10,000)
 - Cardiac rhythm risks

TRAZODONE

- **No studies of hypnotic efficacy beyond 2 weeks**
- **May have more adverse effects than benzodiazepine agonists**
- **Probably does not cause dependency**

MIRTAZAPINE

- Like trazodone, there is evidence that mirtazapine improves sleep.
- A different spectrum of side effects from trazodone
- Not as popular as trazodone for sleep complaints

TCA ANTIDEPRESSANTS

- Not generally recommended for insomnia without depression
- Orthostatic hypotension
- Daytime sedation
- Anticholinergic effects
 - Dry mouth
 - Blurred near vision
 - Urinary retention
 - Constipation
 - Confusion

DOXEPIN

- **Doxepin is possibly effective for sleep in lower doses than other tricyclics (6 mg.), due to antihistaminic properties. An NDA is pending.**

NonBENZODIAZEPINE HYPNOTICS

- **Chloral hydrate**
 - Onset - 1 hour
 - Half-life 4 - 10 hours
- **EEG - Little distortion**
- **Side effects**
 - Gastric irritation - use milk or antacid
 - Organ toxicity - avoid in hepatic, renal or cardiac disease
- **Decreased hepatic metabolism**
- **LD₅₀ - 10gm**
- **Habituation and dependence > 1 week**

ANTIHISTAMINES for INSOMNIA

- **Both OTC and prescription agents used to treat insomnia**
- **Most contain hydroxyzine, diphenhydramine, or doxylamine**
- **May cause insomnia or worsen existing insomnia**
- **All risk negative effects on next-day functioning**

ANTIHISTAMINES for INSOMNIA EFFECTS

- **Onset 45 min - 1 hour**
- **Duration variable - frequently longer than 8 hours**
- **Decreases REM sleep**


ANTIHISTAMINES for INSOMNIA: SIDE EFFECTS

- **Confusion - especially in elderly**
- **Anticholinergic - e.g., urinary retention**
- **AM sedation**
- **Habituation**
- **REM rebound on withdrawal**
 - **Causes and/or worsens insomnia**
 - **Can result in chronic use when acute treatment was planned**



SLEEP APNEA

The most common cause of complaints of excessive sleepiness (falling asleep in the day)





APNEA SYMPTOMS

- **Daytime somnolence**
- **Snoring, often loud**
- **Insomnia Sx (occasionally)**
- **Impaired intellectual functioning**
- **Impaired concentration**
- **Depression**
- **Hypertension**

ASSOCIATED FEATURES

- **obesity**
- **automobile accidents due to sleepiness**
- **hypertension (systemic and pulmonary)**
- **cardiac arrhythmias**




Pathophysiology:

- anatomic factors that reduce lumen size (e.g., **obesity, poor dental development**)
- impairments in central respiratory drive: malfunctioning in neurologic regulation of the muscles that dilate the upper airway during inspiration
- **disordered respiratory feed-back loops**
- **relaxation of phasic muscle activity (e.g, sedative-hypnotics, alcohol)**



collapse of upper airway during inspiration

APNEA



Sleep Apnea Epidemiology In Normal Populations

- **Workers age 30 – 60 years (hypersomnia with apnea)**
 - 2 - 4 % in women
 - 4 - 8 % in men

Young et al, *NEJM*, 1993
- **Population age 40 - 64 years males**
 - Median had 10 sleep breathing events/hr
 - No significant correlation between apneas and daytime well-being was seen in this representative sample

Kripke et al., *Sleep* 1997
- **Over age 65, 80% have at least some mild apneas**

Ancoli-Israel et al., *Sleep* 1981



SLEEP APNEA DETECTION

- Observed patient stops breathing 10 or more seconds
- Patient notices waking up unable to breathe or gasping for air
- All night finger oximetry shows O₂ saturation intermittently dipping



- Snoring, a common sign

APNEA Diagnosis

- **Electroencephalogram**
- **Electromyogram**
- **Respiratory Tracing**
 - (e.g., measurements of oral and nasal airflow with thermistors)
- **Oximetry**
 - (oxygen saturation)
- **Always Useful:**
 - **Electrocardiogram (possibly 24-hour-monitoring)**



TREATMENT of MILD OBSTRUCTIVE SLEEP APNEA


- **Weight loss**
- **Avoid sedative-hypnotics including alcohol at night**
- **Avoid sleeping supine**
 - **A rubber ball sewn into back of patient's night-garment is an effective reminder**




TREATMENT of MODERATE or SEVERE SLEEP APNEA

- **Continuous Positive Airway Pressure** (sometimes bi-level or self-adjusting)
- **Mandibular and tongue advancement oral appliances**
- **Surgery (less proven)**
 - **Uvulopalatoplasties**
 - **Mandibular or maxillary advancement**

CONTINUOUS POSITIVE AIRWAY PRESSURE CPAP TREATMENT



MOUTH APPLIANCES





TREATMENT of CENTRAL SLEEP APNEA

- CPAP: ? risks/benefits
- Low-flow nasal oxygen
- Diaphragmatic pacing
- Medications
 - Estrogen
 - Stimulating antidepressants (protryptiline, desipramine)
 - Acetazolamide

SEDATIVE HYPNOTICS and SLEEP APNEA

- Can push snorer into sleep apnea
- Can worsen sleep apnea
- Can worsen COPD
- Same risks with alcohol
- **BUT, there may be situations where sedative may help**



NARCOLEPSY

- **Irresistible attacks of refreshing sleep that occur almost daily over at least 3 months**
- **Cataplexy**
- **Recurrent intrusions of elements of rapid eye movement sleep into the transition between sleep and wakefulness, as manifested by either hypnopompic or hypnagogic hallucinations or sleep paralysis at the beginning or end of sleep episodes**
- **Nocturnal sleep disturbed**



NARCOLEPSY ETIOLOGY

Largely due to destruction of
hypocretin/orexin neurons

HERITABLE PREDISPOSITION



Chromosome 6: HLA DQB1*0602
Might this HLA type causes susceptibility
to immune destruction of neurons?



NARCOLEPSY TREATMENT

A. Modafinil: rarely associated with substance dependence

B. Stimulants

- Methylphenidate
- Amphetamine: Tolerance more common; highest potential for illicit use

C. Anti-cataplexy agents

- Tricyclic or SSRI antidepressants
- Sodium oxybate

NARCOLEPSY TREATMENT

- **Education**
- **Counseling**
- **Planned naps**
- **Careful sleep hygiene**
- **Group support**



Restless Legs Syndrome (RLS) & Periodic Limb Movement Disorder (PLMD)

- **RLS:**
 - **Legs squirm before sleep; not all-day like akathisia**
 - **Patient complains of onset insomnia**
- **PLMD: rhythmic limb movements**
- **50 - 80% of patients with RLS have PLMD**
- **Genetic factors discovered in 2007**
- **Low iron stores a factor**



Periodic Limb Movement Disorder (PLMD) and Restless Legs Syndrome

- **Benzodiazepines or narcotics**
 - Palliative, not curative
 - Soothes RLS discomfort
 - Increases sleep continuity in PLMD
- **Dopaminergic drugs such as ropinirole and pramipexole**
- **Iron supplementation for ferritin < 50**



CIRCADIAN RHYTHM SLEEP DISORDERS

- **Delayed Sleep Phase Type**
- **Advanced Sleep Phase Type**
- **Jet Lag Type**
- **Shift Work Type**

CIRCADIAN PATHOPHYSIOLOGY

MISALIGNMENT between sleep and biological rhythms



- due to external demands, e.g., night shift
- due to a diminished capacity to respond to rhythm synchronizers (e.g., blind subjects)
- genetic defects in the body clock




SYMPTOMS of DELAYED SLEEP PHASE

- **Can't get to sleep at night**
- **Can't get up in the morning**
- **Tired most of the day**
- **More alert in the evening**

NORMAL:

MELATONIN

TEMPERATURE



---SLEEPY---

NOON 6PM MN 6AM NOON

Preferred Sleep

Sleep and Preferred sleep time aligned

DSPD:

TEMPERATURE

MELATONIN

---SLEEPY---

NOON


6PM

MN

6AM

NOON

Preferred Sleep







Treatments for Delayed Sleep Phase

- **Bright light in the morning:**
 - as soon after arising as possible
- **Vitamin B12: 1-3mg orally daily**
 - Some evidence that B12 phase advances
 - Might augment light treatment
- **Melatonin 0.02-0.20 mg. ~10 hours after arising**


Fluorescent Light Boxes



Light just after waking advances melatonin secretion
and makes sleepiness earlier:




Light just after waking advances melatonin secretion
and makes sleepiness earlier:





PHASE RESPONSE CURVE





SYMPTOMS of ADVANCED SLEEP PHASE

- **Drowsy or falls asleep early in the evening**
- **Awakens too early in the morning**
- **Most energetic in the morning**

TREATMENT of ADVANCED SLEEP PHASE

- **Use brighter light in the evening**
 - **just before bedtime**
- **Sometimes 50 - 100 watts
fluorescent is sufficient**
 - **Usually best near the television**



MELATONIN:

Used by 5% of the population

**A night hormone which makes
animal gonads atrophy and can
turn fur white.**

**Melatonin is not hypnotic: nocturnal
rodents have high melatonin when
they are most alert.**



MELATONIN RISKS

- **Long-term safety in humans not established:**
 - **Probably causes gonadal suppression in young men and women and may cause infertility**
 - **Suspected risks of seizure, myocardial infarction, or stroke**
 - **Purity and potency of over-the-counter preparations is variable**
 - **Might protect against or cause cancer**



MELATONIN for INSOMNIA

- **Effectiveness and safety not demonstrated for chronic insomnia**
- **Limited evidence of minor short-term benefits**
- **Some meta-analyses not favorable**

USES of MELATONIN

- **Jet lag:** weak efficacy (some, not all studies), but not without side effects
- **Shift work:** weak efficacy in some studies. No studies beyond a few days



SHIFT WORK

- **An increasing percentage of the population**
- **Impairs sleep and night performance**
- **Possibly associated with depression and shortened life**
- **Accidents**

SHIFT WORK TREATMENT

- Melatonin is not as effective as bright light for treatment of night shift work (<1 week studies)
- Long-term studies not available
- Adjustment to night shifts is helped by wearing orange (blue-block) glasses when driving home in the morning.



FATIGUE – RELATED AUTO ACCIDENTS





RESIDENTS!

- **GET PLENTY OF SLEEP!**
- **AFTER NIGHT SHIFTS, BE CAREFUL DRIVING HOME!**

Post Lecture Exam

Question 1

1. The most common cause of insomnia is
 - A. Use of sleeping pills
 - B. Poor sleeping habits
 - C. Psychiatric Disturbance
 - D. Alcoholism
 - E. Sleep apnea

Question 2

- 2. Effective treatment for chronic insomnia may include:**
- A. Zaleplon
 - B. Sleep restriction therapy
 - C. Zolpidem
 - D. Quazepam
 - E. Triazolam

Question 3

- 3. Benefits of hypnotics outweigh risks:**
- A. For insomnia due to medical conditions
 - B. For hospice care
 - C. To prevent depression
 - D. To improve daytime alertness
 - E. All of the above

Question 4

- 4. A hypnotic which causes little daytime sedation is:**
- A. Lorazepam
 - B. Zolpidem
 - C. Temazepam
 - D. Flurazepam
 - E. Diphenhydramine

Question 5

- 5.** The usual maximum dose of zolpidem for an elderly woman is
- A. 6.25 mg
 - B. 10 mg
 - C. 15 mg
 - D. 20 mg
 - E. 25 mg

Question 6

- 6. The most popular drug for sleep complaints accompanying depression is:**
- A. Zolpidem
 - B. Zaleplon
 - C. Trazodone
 - D. Melatonin
 - E. Temazepam

Question 7

- 7. A hypnotic which helps people fall asleep when taken at bedtime is:**
- A. Zaleplon
 - B. Temazepam
 - C. Lorazepam
 - D. Oxazepam
 - E. Ethchlorvynol

Question 8

- 8. The most common cause of excessive sleep is:**
- A. Primary hypersomnia
 - B. Depression
 - C. Tricyclic antidepressants
 - D. Sleep apnea
 - E. Irregular habits

Question 9

- 9. Useful treatments for sleep apnea include:**
- A.** Mandible and tongue appliances
 - B.** Dieting
 - C.** Sleep position training
 - D.** Continuous positive airway pressure
 - E.** All of the above

Question 10

10. To treat delayed sleep phase, use:

- A. Vitamin B6
- B. Relaxation and sleep hygiene
- C. Methylphenidate
- D. Bright light in the morning
- E. Bright light just before bedtime

Answers to Pre & Post Competency Exams

1. C

2. B

3. B

4. B

5. A

6. C

7. A

8. D

9. E

10. D